BIO stock · MSFT stock · Lician Pro · $19.99/mo or $149/yr

BIO vs MSFT · P/E 43, rev $2.58B vs rev $331.84B

Bio-Rad Laboratories (BIO) versus Microsoft Corporation (MSFT) — a side-by-side from cached financials, not a winner call.

Bio-Rad Laboratories (BIO) common stock.

Microsoft Corporation (MSFT) is a software - infrastructure company listed on US. It is led by Satya Nadella.

Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. BIO currently screens at trailing P/E 43.1.

Latest reported MSFT revenue for 2026-06-30 was $331.84B. Net income was $133.75B. Revenue was up 17.8% from 2025-06-30 to 2026-06-30. MSFT currently screens at market cap $3.71T.

BIO currently screens at trailing P/E 43.1. MSFT currently screens at market cap $3.71T.

Not investment advice. Open the BIO and MSFT stock pages for the full models.

Basic comparison

Price, market cap, and trailing P/E stay on this page.

BIO vs MSFT
MetricBIOMSFT
Price$353.70$529.05
Market cap—$3.71T
Trailing P/E43.1—

Deeper peer metrics

Net income and multi-year revenue growth are the peek. More peer metrics open below. This block stops at the labels.

More peer metrics

Operating margin, EPS, free cash flow, and gross margin are on Pro.

Unlock deeper peer metrics

BIO vs MSFT comparison FAQ

What is BIO's P/E ratio?

Bio-Rad Laboratories (BIO) screens at trailing P/E 43.1.

What is MSFT's market cap?

Microsoft Corporation (MSFT) currently screens at market cap $3.71T.

What is BIO's latest revenue?

Latest reported BIO revenue for 2025-12-31 was $2.58B.

What is MSFT's latest revenue?

Latest reported MSFT revenue for 2026-06-30 was $331.84B.

What is BIO's net income?

Net income was $759.9M for Bio-Rad Laboratories (BIO).

What is MSFT's net income?

Net income was $133.75B for Microsoft Corporation (MSFT).

How did MSFT revenue change on this page?

Revenue was up 17.8% from 2025-06-30 to 2026-06-30.

Where is the BIO vs MSFT comparison listed?

The cached BIO vs MSFT comparison is listed at https://lician.com/compare/bio-vs-msft.

Not investment advice.

Popular Stock Comparisons